It's not just Charles Lieber: NI­H's on­go­ing in­ves­ti­ga­tion has swept up 54 sci­en­tists who vi­o­lat­ed rules about for­eign ties

Michael Lauer NIH

The NIH’s work­ing group for for­eign in­flu­ences on re­search in­tegri­ty has opened cas­es against 189 sci­en­tists sus­pect­ed of vi­o­la­tions re­lat­ed to over­seas ties since launch­ing an on­go­ing, sweep­ing in­ves­ti­ga­tion al­most two years ago, new­ly avail­able sta­tis­tics showed, lead­ing to the ter­mi­na­tions and res­ig­na­tions of 54 sci­en­tists.

Of those who have been in­ves­ti­gat­ed, 41% have al­so been re­moved from the NIH sys­tem, barred from seek­ing fur­ther grants. Michael Lauer, NIH’s head of ex­tra­mur­al re­search, pre­sent­ed a com­pre­hen­sive set of these and oth­er num­bers in a vir­tu­al up­date on Fri­day, just a day af­ter Charles Lieber — the for­mer head of Har­vard’s chem­istry de­part­ment — was in­dict­ed in fed­er­al court for ly­ing about his Chi­nese con­nec­tions.

While high-pro­file cas­es like Lieber’s, as well as those at MD An­der­son, Emory Uni­ver­si­ty and Mof­fitt be­fore him, have gripped the bio­med­ical field, they mere­ly rep­re­sent in­di­vid­ual snap­shots of when in­sti­tu­tions re­spond to the NIH’s warn­ings about hid­den for­eign ties. The of­fi­cial da­ta shine light on the broad­er pic­ture.

Fran­cis Collins NIH

For one, more could be com­ing. The NIH has iden­ti­fied 399 sci­en­tists of pos­si­ble con­cern in to­tal, 251 of whom screened “pos­i­tive,” with an­oth­er 72 “pend­ing.”

Agency di­rec­tor Fran­cis Collins called that pic­ture “sober­ing,” ac­cord­ing to Sci­ence, which first re­port­ed on Lauer’s re­marks.

At the heart of the is­sue, Lauer high­light­ed, isn’t that US re­searchers are col­lab­o­rat­ing with in­ves­ti­ga­tors in for­eign coun­tries. Rather, it’s of­ten about NIH-backed sci­en­tists’ fail­ure to dis­close sig­nif­i­cant re­sources from al­ter­na­tive sources, con­flicts of in­ter­est or patents. In cer­tain cas­es, there were even peer re­view vi­o­la­tions.

Over­all, Chi­na stood out as the top coun­try pro­vid­ing for­eign sup­port to sci­en­tists, ei­ther re­flect­ing or con­firm­ing the long­stand­ing rhetoric on aca­d­e­m­ic es­pi­onage. Pre­sum­ably through the Thou­sand Tal­ents Pro­gram, Chi­nese fund­ing was in­volved in 93% of the cas­es.

It may thus be un­sur­pris­ing that the vast ma­jor­i­ty of cas­es in­volve an Asian man in his 50s, al­though 14% of the in­ves­ti­ga­tions cen­tered around whites. On av­er­age, the NIH has is­sued $678,000 in grant sup­port to each of these sci­en­tists, who are spread across 27 states and 59 cities.

But there is hope that in­sti­tu­tions are grow­ing more aware of the prob­lems — which might not have pre­vi­ous­ly been con­sid­ered se­ri­ous un­til the FBI and the NIH cracked down on them — and tak­ing ac­tions against non-com­pli­ance. As part of their ef­forts, the NIH has con­tact­ed 87 uni­ver­si­ties or re­search cen­ters; slight­ly more than half men­tioned they are im­ple­ment­ing new mea­sures.

In a nod to con­cerns that the height­ened sen­ti­ments are stok­ing fears among sci­en­tists of Asian her­itage who fear they may be tar­get­ed, Lauer made sure to tuck this re­as­sur­ance to the end of his slides:

We re­it­er­ate the im­por­tance of the con­tri­bu­tion of for­eign sci­en­tists to bio­med­ical re­search; we must not cre­ate a cli­mate that is un­wel­com­ing to them.

Illustration: Assistant Editor Kathy Wong for Endpoints News

How Pur­due's $272M ad­dic­tion pay­out fund­ed a new home for its dis­card­ed non-opi­oid re­search

Don Kyle spent more than 20 years working for Purdue Pharma, right through the US opioid epidemic that led to the company’s rise and eventual infamy. But contrary to Purdue’s focus on OxyContin, Kyle was researching non-opioid painkillers — that is, until the company shelved his research.

As the company’s legal troubles mounted, Kyle found an unlikely way to reboot the project. In 2019, he took his work to an Oklahoma State University center that’s slated to receive more than two-thirds of the state’s $272 million settlement with Purdue over claims that the drugmaker’s behavior ignited the epidemic of opioid use and abuse.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

President Joe Biden at the State of the Union address with Vice President Kamala Harris and House Speaker Kevin McCarthy (Patrick Semansky/AP Images)

The drug pric­ing pres­i­dent: Biden warns of ve­to for any IRA re­peal at­tempts

President Joe Biden made clear in his “finish the job” State of the Union address last night that one of those jobs to be finished is insulin prices.

Biden’s push again to tackle insulin prices, after Republicans rebuffed the idea last summer and just after Biden won Medicare drug price negotiations/caps via the Inflation Reduction Act, shows how heavily he’s leaning into this work.

Rupert Vessey, Bristol Myers Squibb head of research and early development

Up­dat­ed: R&D tur­bu­lence at Bris­tol My­ers now in­cludes the end of a $650M al­liance and the de­par­ture of a top re­search cham­pi­on

This morning biotech Dragonfly put out word that Bristol Myers Squibb has handed back all rights to its IL-12 clinical-stage drug after spending $650 million to advance it into the clinic.

The news arrives amid a turbulent R&D stage for the pharma giant, which late last week highlighted Rupert Vessey’s decision to depart this summer as head of early-stage R&D following a crucial three-year stretch after he jumped to Bristol Myers in the big Celgene buyout. During that time he struck a series of deals for Bristol Myers, and also shepherded a number of Celgene programs down the pipeline, playing a major role for a lineup of biotechs which depended on him to champion their drugs.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Bill Haney, Dragonfly CEO (Dave Pedley/Getty Images for SXSW)

Drag­on­fly chief: Bris­tol My­ers shouldn’t blame IL-12’s clin­i­cal per­for­mance for de­ci­sion to scrap the deal — eco­nom­ics played a key role

Bristol Myers Squibb says the IL-12 drug they were developing out of Dragonfly Therapeutics was scrubbed from the pipeline for a simple reason: It didn’t measure up on clinical performance.

But Bill Haney, the CEO of Dragonfly, is taking issue with that.

The early-stage drug, still in Phase I development, has passed muster with Bristol Myers’ general clinical expectations, advancing successfully while still in Phase I, he says.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Utpal Koppikar, new Verily CFO

Ex­clu­sive: Ver­i­ly wel­comes Atara Bio­ther­a­peu­tics vet­er­an as new CFO

Verily, Alphabet’s life sciences outfit, has plucked a new CFO from the ranks of Atara Biotherapeutics, the company announced on Wednesday.

Utpal Koppikar joins Verily after a nearly five-year stint as CFO and senior VP at Atara, though his résumé also boasts roles at Gilead and Amgen.

The news follows a major reshuffling at Verily, including several senior departures earlier this year and a round of layoffs.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.

Singer Nick Jonas is back at work for Dexcom, this time for its new G7 glucose monitor.

Dex­com's spokescelebri­ty Nick Jonas re­turns to Su­per Bowl in new glu­cose mon­i­tor com­mer­cial

Dexcom is going back to the Super Bowl with its pop singer and patient spokesperson Nick Jonas. Jonas takes center stage as the lone figure in the 30-second commercial showcasing Dexcom’s next-generation G7 continuous glucose monitoring (CGM) device.

Jonas’ sleight-of-hand tricks populate the commercial — he pinches his empty fingers together and pops them open to reveal the small CGM — even as he ends the ad, saying, “It’s not magic. It just feels that way.” Jonas then disappears in a puff of smoke.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.

Richard Francis, newly-appointed Teva CEO (Novartis via Facebook)

New Te­va CEO Richard Fran­cis repri­or­i­tizes to 'get back to growth'

Six weeks into his new role at the helm of Teva Pharmaceutical, Richard Francis said it’s time to “get back to growth,” starting with a good look at the company’s priorities.

The chief executive has kicked off a strategic review, he announced during Teva’s quarterly call, which will continue over the next several months and produce results sometime in the middle of 2023. That means some pipeline cuts may be in store, he told Endpoints News, while declining to offer much more detail.

FDA Commissioner Robert Califf on Capitol Hill, Feb. 8, 2023 (Drew Angerer/Getty Images)

FDA com­mis­sion­er floats ideas on how to bet­ter han­dle the pan­dem­ic

FDA Commissioner Rob Califf joined the heads of the CDC and NIH in the hot seat today before a key House subcommittee, explaining that there needs to be a much faster, more coordinated way to oversee vaccine safety, and that foreign biopharma inspections, halted for years due to the pandemic, are slowly ramping up again.

Califf, who stressed to the House Energy and Commerce’s Subcommittee on Health that the CDC also needs better data, made clear that the FDA’s ability to monitor the safety of vaccines “would also benefit greatly by a coordinated federal public health data reporting authority.”

Sanofi is renewing its #VaccinesForDreams campaign with more stories, such as Juan's in Argentina (Sanofi)

Sanofi re­news so­cial cam­paign to re­mind that vac­cines let peo­ple ‘Dream Big’

Sanofi is highlighting people’s dreams — both big and small — to make the point that vaccines make them possible.

The renewed “Dream Big” global social media campaign’s newest dreamer is Juan, a teacher in the Misiones rainforest in Argentina whose story is told through videos on Instagram and Sanofi’s website with the hashtag #VaccinesForDreams.

The campaign ties to Sanofi’s broader umbrella initiative “Vaccine Stories” to promote the value of vaccines and drive awareness of the need for improved vaccination coverage.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.